Polycythemia Vera (PV) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Polycythemia Vera Emerging Therapy and TPP Insights

Thelansis’s “Polycythemia Vera (PV) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Polycythemia Vera Overview

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm, usually caused by an acquired JAK2 mutation, most often JAK2 V617F, driving clonal red-cell overproduction. Raised hematocrit increases blood viscosity and the risk of arterial and venous thrombosis. Symptoms include headache, dizziness, fatigue, itching after bathing and splenomegaly. Some patients develop post-PV myelofibrosis or acute myeloid leukemia. Treatment aims to prevent thrombosis and keep hematocrit below 45%, generally with low-dose aspirin and phlebotomy. Higher-risk patients may need cytoreduction with hydroxyurea or interferon; ruxolitinib is an option for selected patients resistant or intolerant to hydroxyurea. In August 2026, the FDA approved rusfertide (MIMRYLO), a hepcidin mimetic, for erythrocytosis in adults with PV, offering another way to reduce phlebotomy burden. It does not eradicate the malignant clone; long-term disease control remains challenging. White-cell and platelet counts may also rise.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)